P. 67-72Autonomic disorders are often seen in Parkinson's disease, with disturbances of the gastrointestinal tract occurring most frequently. These disorders, mainly a delay in gastric emptying and slowed gastrointestinal motility, can modify the pharmacokinetics and effectiveness of drugs used to treat Parkinson's disease and administered orally. In this study, we evaluated in a rabbit model the pharmacokinetics of levodopa (administered with carbidopa) in the context of gastrointestinal motility slowed by the administration of an anticholinergic drug. Levodopa+carbidopa (20:5 mg/kg) and the anticholinergic biperiden (100 μg/kg) were orally administered to rabbits over one of two time periods (7 or 14 days) to verify the stabilizatio...
Although levodopa was introduced almost 30 years ago it still represents the first-choice treatment ...
The duration of action of oral levodopa becomes shorter as Parkinson’s disease (PD) progresses. Pati...
P. 296-305Background: Plantago ovata husk therapy could be used in patients with Parkinson disease t...
P. 1434-1442Gastrointestinal dysfunction is common in Parkinson’s disease. Fiber therapy could be u...
Levodopa uptake from the gastrointestinal tract in patients with Parkinson’s disease (PD) can be aff...
Motor complications of Parkinson's disease (PD) are a consequence of pulsatile dopaminergic stimulat...
Parkinson's disease is the second-most common neurodegenerative disorder worldwide. Besides decipher...
Introduction: Levodopa (LD) is important in the clinical treatment of Parkinson's disease (PD), and ...
Introduction Gastrointestinal dysfunction is often described in patients with Parkinson disease (PD)...
P. 451-457Levodopa pharmacokinetics show i111portanl inter- and intraindividual dijferences when it ...
Objectives: Better understanding dyspepsia in Parkinson’s disease (PD) in order to improve patients ...
none14siBackground: Levodopa-carbidopa intestinal gel (LCIG) treatment has shown variable effect on ...
Parkinson’s disease (PD) is characterized by degeneration of dopaminergic cells, which results in do...
Levodopa is the gold standard in the pharmacological treatment of Parkinson's disease (PD) and its o...
PhD ThesisBackground: Parkinson’s disease (PD) can result in impaired motility throughout the gastro...
Although levodopa was introduced almost 30 years ago it still represents the first-choice treatment ...
The duration of action of oral levodopa becomes shorter as Parkinson’s disease (PD) progresses. Pati...
P. 296-305Background: Plantago ovata husk therapy could be used in patients with Parkinson disease t...
P. 1434-1442Gastrointestinal dysfunction is common in Parkinson’s disease. Fiber therapy could be u...
Levodopa uptake from the gastrointestinal tract in patients with Parkinson’s disease (PD) can be aff...
Motor complications of Parkinson's disease (PD) are a consequence of pulsatile dopaminergic stimulat...
Parkinson's disease is the second-most common neurodegenerative disorder worldwide. Besides decipher...
Introduction: Levodopa (LD) is important in the clinical treatment of Parkinson's disease (PD), and ...
Introduction Gastrointestinal dysfunction is often described in patients with Parkinson disease (PD)...
P. 451-457Levodopa pharmacokinetics show i111portanl inter- and intraindividual dijferences when it ...
Objectives: Better understanding dyspepsia in Parkinson’s disease (PD) in order to improve patients ...
none14siBackground: Levodopa-carbidopa intestinal gel (LCIG) treatment has shown variable effect on ...
Parkinson’s disease (PD) is characterized by degeneration of dopaminergic cells, which results in do...
Levodopa is the gold standard in the pharmacological treatment of Parkinson's disease (PD) and its o...
PhD ThesisBackground: Parkinson’s disease (PD) can result in impaired motility throughout the gastro...
Although levodopa was introduced almost 30 years ago it still represents the first-choice treatment ...
The duration of action of oral levodopa becomes shorter as Parkinson’s disease (PD) progresses. Pati...
P. 296-305Background: Plantago ovata husk therapy could be used in patients with Parkinson disease t...